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Myoﬁbroblastictumor,alsoknownasinﬂammatorypseudotumororpseudosarcoma,isabenigntumorwithmesenchymalorigin.
Bladder location is very uncommon. We report the case of a 58-year-old man with a history of von Recklinghausen’s disease who
complained for painless macroscopic hematuria 5 months after suprapubic prostatectomy. The radiograph evaluation revealed a
bladdertumor,andthepathologicexaminationfollowingatransurethralresectionshowedinﬂammatorymyoﬁbroblastictumorof
thebladder. Thepatient ﬁnallyunderwent aradical cystectomy dueto theuncertain pathogenesis of inﬂammatory myoﬁbroblastic
tumor as well as the rarity of cases published on bladder tumors in Von Recklinghausen’s patients.
1.Introduction
Inﬂammatory myoﬁbroblastic tumor (IMT) or inﬂamma-
torypseudotumor(IP)oftheurinarybladderisararebenign
nonepithelial lesion. This type of tumor has been described
in several organs and anatomical sites including lung, head,
neck, and brain. In the genitourinary system, the tumor
usually originates in the bladder [1], but it has also been
reported in the kidney, urethra, prostate, ureter, and rete
testis. It was Roth in 1980 who ﬁrst described such a lesion
in the genitourinary tract [2], followed by Proppe et al. who
reported similar ﬁndings in eight patients who had recently
undergone a surgical procedure. The term “postoperative
spindle cell nodule” (PSCN) was used to deﬁne the reactive
process within three months of a surgical procedure at
the site it derives [3]. Inﬂammatory pseudotumor (IP) on
the other hand is histologically similar to PSCN, but the
diagnosis is made in the absence of prior surgery [4, 5].
Regarding patient’s prognosisa it is important to distinguish
and diﬀerentiate this lesion from sarcoma, fact that can be
diﬃcult both clinically and histologically. The case presented
hereistheﬁrstofIMTinapatientwithVonRecklinghausen’s
neuroﬁbromatosis.
2. Case Presentation
A ﬁfty-eight-year old man was evaluated for painless macro-
scopic hematuria. The patient had a family history of von
Recklinghausen’s disease with the typical multiple cutaneous
neuroﬁbromas. Initial abdominal ultrasound revealed a
tumor on the bladder dome which was conﬁrmed by a
subsequent cystoscopy. A CT scan of the abdomen showed
no perivesical tissue extension, no lymph node enlargement
and no hydronephrosis presence (Figure 1). Due to its
uncommon endoscopically features and extension of the
lesion (large base, smooth surface, and approximate size
>3cm) the patient underwent an incomplete transurethral
resection of the tumor for staging purposes and to deﬁne its
origin. Histopathology following tumor resection depicted a
neoplasm of mesenchymal origin with immunohistochemi-
cal ﬁndings indicating the diagnosis of inﬂammatory myoﬁ-
broblastic tumor (IMT). Vimentin was diﬀusely expressed in
neoplastic cells and desmin, α-SMA, s-100, CD117, CD34
and keratins of low molecular weight were focally positive.
(Figures 2(a) and 2(b)). On the other hand CD30, NSE
and keratins of high molecular weight were not expressed at
all.2 Case Reports in Medicine
Figure 1: Computed tomography of the lower abdomen showing
an exophytic lesion arising from the dome of the bladder (black
arrow) and two large diverticulums (white arrows).
(a)
(b)
Figure 2: The immunohistochemical staining proﬁle of the tumor
(a) APAP/ a-SMA X 25, and (b) APAP/S-100 X 25.
Interestingly, our patient had a recent 5-month history of
suprapubic prostatectomy due to lower urinary tract symp-
toms, during which no bladder wall pathology was recorded.
In addition, preprostatectomy imaging was reviewed and
quoted as normal. Although the diagnosis of inﬂammatory
pseudotumor could be made, the patient was consented
for the uncertain biological behavior and the malignant
potential of the tumor. Upon discussing deﬁnitive treatment
the patient decided to undergo radical cystectomy. As a con-
sequence,radicalcystectomyfollowedbyanilealconduitwas
performed.Additionallyduetolackofgenetictesttoconﬁrm
his inherited disease, the excised cutaneous lesions from the
site of the performed stoma were sent for histopathologic
evaluation (Figure 3). Macroscopic view of the cystectomy
specimen revealed two polypoid lesions with smooth, elastic
surface, 1 and 1,5cm in diameter located at the bladder
dome (Figure 4(a)). The ulcerated surface of the polypoid
lesion was recognized microscopically (Figure 4(b)). The
microscopic and immunochemistry ﬁndings conﬁrmed the
initial diagnosis after the transurethral resection of the
lesion.
3. Discussion
Inﬂammatory myoﬁbroblastic tumor or pseudotumor is a
rare neoplasm believed to be benign. Among the genitouri-
nary organs, the bladder is more commonly aﬀected; still,
this entity is extremely rare. Adult males are predominated
but the disease can also aﬀect children and elderly patients.
Painlesshematuriaisthemostcommonpresentingsymptom
followed by lower urinary tract symptoms and chronic
pelvic pain. Rarely does it constitute an incidental ﬁnding
during radiological examination. Predisposing or exacerbat-
ing factors of genitourinary manifestation include cigarette
smoking and prior surgery in the form of an endoscopic
bladder surgery or an open gynecological intervention of the
pelvis [6, 7].
IMT should be diﬀerentiated from benign lesions such
as leiomyoma or solitary ﬁbrous tumors (SFTs), and malig-
nant lesions such as leiomyosarcoma, sarcomatoid carci-
noma, or rhabdomyosarcoma. These entities share common
histopathological ﬁndings. However, their clinical behavior
is entirely diﬀerent. To properly diﬀerentiate immunochem-
istry is essential. Anaplastic lymphoma kinase (ALK) which
stains positive in approximately half of the IMT cases is a
promising marker under investigation [1].
Neuroﬁbromatosis type-1 (NF-1) is a familial autosomal
dominant syndrome characterized by multiple cutaneous
neuroﬁbromas and caf´ e au lait spots, skeletal abnormalities,
and nervous system manifestations. Urinary tract is rarely
involved with the most common manifestation being the
development of neuroﬁbromas [8]. Two cases of non-
epithelial bladder tumors, one leiomyosarcoma [9]a n do n e
solitary leiomyoma [10], have been published. Alterations in
the expression of NF-1 gene and of several growth factors
may explain the development of mesenchymal tumors in
thesepatients.Ourpatienthasalsobeenoperatedonandthis
could activate the process of tumor formation, according to
the term “postoperative spindle cell nodule.”
Bladder inﬂammatory myoﬁbroblastic tumors follow
a benign indolent course are treated conservatively by
transurethral resection or partial cystectomy. Followup con-
stitutes of repeated cystoscopies and biopsies to conﬁrm
complete disease remission. When IMT is clearly distin-
guished from aggressive lesions such as sarcomas radical
surgery, radiation or chemotherapy could be considered as
overtreatment [1, 7].
Thepatientwasfullyinformedandconsentedtoundergo
radical cystectomy. The decision was based on the rarity
and the unknown natural history of IMT as well as the
scarce cases published on bladder tumors in Von Reckling-
hausen’s patients. Alternative therapeutic approaches could
betransurethralresectionofthetumororpartialcystectomy.
However the relapse rate following these treatments rangesCase Reports in Medicine 3
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Figure 3: (a) Numerous cutaneous neuroﬁbromas (small white arrows) and the performance of the ileal stoma (black arrow) located below
the right line between umbilicus and the anterior superior iliac spine. (b) Microscopic view of resected cutaneous neuroﬁbroma at the site
of the performed stoma (H-E stain X 2.5).
(a) (b)
Figure 4: (a) Intraluminal macroscopic view of cystectomy specimen. Recognition of one out of the two polypoid lesions of urinary mucosa
(white arrow). (b) Microscopic view of the ulcerated surface of the polypoid lesion (H-E stain X 2.5).
between 10% and 30% at a mean follow-up time of
approximately 30 months [6, 7]. Although radical cystec-
tomyisanaggressivetherapeuticoption, minimizing therisk
of grade and stage progression may optimize patient’s long-
term outcome.
Consent
Written informed consent was obtained from the patient for
publication of this paper and accompanying images. A copy
of the written consent is available for review by the Editor-
in-Chief of this journal.
Abbreviations
IMT: Inﬂammatory myoﬁbroblastic tumor
IP: Inﬂammatory pseudotumor
PSCN: Postoperative spindle cell nodule
CT: Computed tomography
α-SMA: α-Smooth muscle actine
NSE: Neuron-speciﬁc enolase
SFT: Solitary ﬁbrous tumors
ALK: Anaplastic lymphoma kinase
NF-1: Neuroﬁbromatosis type-1.
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